Alternatives to traditional freeze-drying may reshape biological development and the cold chain.

Beyond Lyophilization

A clinical-stage company produces adeno-associated virus vectors in-house.

Finding Success in AAV Manufacturing

Manufacturing increases but future demand remains unpredictable.

Meeting Demand for Vials and Syringes

Topic

Articles

Vetter and Rentschler Biopharma have announced the strengthening of their strategic alliance.

Vetter and Rentschler Biopharma Strengthen Strategic Alliance

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

ViroCell Launched in the UK to Manufacture Viral Vectors

ADMA will now have the ability to produce Bivigam at an expanded capacity with the same manufacturing scale, while using the same equipment, release testing assays, disposables, and labor force.

FDA Approves ADMA Biologics’ Expanded Manufacturing Process for Intravenous Immune Globulin

AkesoBio’s expanded manufacturing capacity, enabled by the addition of another Cytiva FlexFactory platform, will be used to meet current and future market needs in China as well as worldwide.

Cytiva Provides Another FlexFactory Single-Use Platform for AkesoBio’s Manufacturing Expansion

In addition to the traditional FOYA category awards, ISPE recognized two facilities for operational agility during the COVID-19 pandemic.

ISPE Announces 2021 FOYA Category Winners

With a $5 million grant from DARPA, DNA Script and Moderna will develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA’s Nucleic Acids On-Demand World-Wide program.

DNA Script to Team up With Moderna for Vaccine and Therapeutic Manufacturing for DARPA

Samsung and TG Therapeutics have expanded their 2018 contract manufacturing deal for the supply of TG’s ublituximab, an investigational anti-CD20 monoclonal antibody. 

Samsung and TG Therapeutics to Expand mAb Manufacturing Collaboration 

DCAT’s annual bio/pharmaceutical development and manufacturing business event, DCAT Week, will take place virtually from July 12–16, 2021, with the in-person even postponed to March 20–24, 2022 in New York City. 

DCAT Week to be Held Virtually; In-Person Event Postponed 

Design for a new BMS multi-product cell therapy manufacturing site in Leiden is underway, with construction to start later in 2021.

Bristol Myers Squibb Plans Cell Therapy Manufacturing Site in the Netherlands

Vertex and CRISPR have amended their collaboration agreement to include the development, manufacture, and commercialization of CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Agreement for $1.1 Billion

Cleanroom Equipment and Supplies

Clinical Trial Materials